NeuroScientific Biopharmaceuticals (ASX: NSB) is exploring the potential of its newly acquired StemSmart stem cell technology for treating complex conditions such as refractory Crohn’s disease and steroid-refractory graft-versus-host disease (GVHD). NeuroScientific Biopharmaceuticals is a company focused on discovering and developing peptide-based pharmaceutical drugs. Their aim is to address significant unmet medical needs, particularly in areas like neuroprotection and neuroregeneration.
The company recently completed the acquisition of Isopogen WA, which developed the patented StemSmart technology. This technology is used to manufacture mesenchymal stromal cells (MSC) derived from adult human donor bone marrow. These cells are isolated, cultured, and then processed using StemSmart to enhance their clinical effectiveness. Prior to the acquisition, NeuroScientific reviewed existing studies to identify other conditions that could benefit from StemSmart.
Early data from a Phase 2 trial involving 18 patients with refractory Crohn’s disease suggests that StemSmart MSC can be potent, efficacious, and safe. The majority of patients experienced clinical improvement, with some achieving clinical remission. NeuroScientific has initiated work investigating fistulising Crohn’s disease under a special access scheme (SAS). This scheme may provide early access to StemSmart for patients needing alternative treatments with minimal side effects. If successful, the company could advance to a Phase 1/2 clinical trial.
In a Phase 1 clinical trial of StemSmart MSC on adults and children with steroid-refractory GVHD, most patients responded to the therapy with complete or partial resolution of symptoms and improved survival rates. Ten children treated on compassionate grounds all survived to 12 months post-transplant, exceeding anticipated mortality rates. Three chronic GVHD patients remain alive more than six years post-treatment. The trial findings support the use of StemSmart MSC therapy for severe steroid-refractory GVHD, given the poor outlook for these patients.
